bullish
BeiGene (6160.HK/BGNE.US) 24Q3 - Things Are on Track Despite BRUKINSA’s Disappointing QoQ Growth
172 Views14 Nov 2024 08:55
BRUKINSA's QoQ growth slowed in 24Q3, but still outperformed peers.Full-year revenue forecast adjusted to $3.7 billion.Peak sales projected at $5.5 billion. Reasonable valuation is $18.5-27.5 billion
What is covered in the Full Insight:
- Introduction to BeiGene 24Q3 Results
- BRUKINSA's Market Performance
- Tislelizumab Sales Analysis
- Financial Overview and Forecast
- Strategic Considerations and Challenges
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- BeiGene (6160.HK/BGNE.US) 24Q2 - It Is Time to Open a New Chapter in China's Pharmaceutical Industry12 Aug 2024
- BeiGene (6160.HK/BGNE.US/688235.CH) 24Q1- A Breakeven Point Is on the Horizon, but It Is Not Stable13 May 2024
- BeiGene (6160.HK/BGNE.US/688235.CH) - Pain Points Behind the High Growth05 Mar 2024
x